You are viewing a free version of BCIQ, BioCentury's advanced business intelligence database for the biopharma industry.
Find partnering and investment opportunities, uncover and track competitive threats, dive into a company's financing and deal history, its pipeline and molecular targets of interest, and much more. Enter a Company name above to access free BCIQ profiles. Request a trial to unlock the full value of BCIQ.
Canaan

BioCentury | Jul 26, 2018

Financial News

Liquidia prices $50M IPO

...a powder formulation of treprostinil delivered via dry powder inhaler. Shareholders include New Enterprise Associates, Canaan...

BioCentury | Jun 10, 2021

Finance

Cytokine companies Synthekine, Bright Peak each tap crossovers for megarounds

...includes Rock Springs Capital, Omega Funds, TCG Crossover, Lilly Asia Ventures, The Column Group, Samsara BioCapital, Canaan...

BioCentury | May 04, 2021

Product Development

With an eye toward M&A, Vivace aims to establish POC for emerging solid tumor target TEAD

...pathway inhibitors, though neither has disclosed pipeline programs.Vivace’s 2015 series A round was led by Canaan...

BioCentury | Apr 23, 2021

Emerging Company Profile

Tyra: designing kinase inhibitors resistant to mutations

...mutations.Nina Kjellson —a general partner at Canaan...

BioCentury | Apr 17, 2021

Deals

April 16 Quick Takes: AZ’s $39B Alexion deal clears FTC hurdle; plus Biosplice, C2i, Relay, Surrozen and more

...also disclosed that it had raised $25 million in a series A round backed by Canaan...

BioCentury | Mar 31, 2021

Finance

March 31 Quick Takes: Muted reception for Achilles in market debut; plus BridgeBio-Helsinn, Scribe, Outpace, OnQuality, AffaMed, Treos

...RiverVest Venture Partners, Qatar Investment Authority, Redmile Group, 3B Future Health Fund (Helsinn Investment Fund), Canaan...

BioCentury | Dec 17, 2020

Finance

Dec. 16 Quick Takes: Neurogene raises $115M while BioAtla sees first-day pop; plus fundings for Atsena, MinervaX, Vivace, Arvinas

...$30 million series C round, which also featured first-time investor RA Capital and returning investor Canaan...

BioCentury | Oct 15, 2020

Finance

Larger stakes, more newcos as Canaan moves to bump up biopharma investments with new $800M fund

...new $800 million fund dedicated to healthcare, Canaan...
...of our healthcare investments —in biopharma,” Canaan...
...20-25% ownership with the initial investment.Within therapeutics, Canaan’s...

BioCentury | Oct 13, 2020

Finance

Oct. 13 Quick Takes: Sovereign wealth fund backs Evotec; plus Canaan, EdiGene, Cedilla, Rappta and Lassogen

...on frequent partnerships with biopharmas around its preclinical platform and services, climbed €0.98 to €23.57 on Tuesday.Canaan...
...is developing lasso peptides for cancer, autoimmunity, pain and inflammation. TargetsPP2A – Protein phosphatase 2A BC Staff Evotec SE Canaan Cedilla...

BioCentury | Sep 23, 2020

Management Tracks

Gilead BD head Bender takes top job at pediatric cancer start-up Day One

...Bowers to head commercial as Canaan-incubated biotech builds out team   By  Karen Tkach Tuzman, Associate Editor...
...Karen Tkach Tuzman, Associate Editor With ex-Gilead BD head Jeremy Bender on board as CEO, Canaan-incubated...
...him a bird's-eye view of oncology opportunities across industry.Bender succeeds acting CEO Julie Grant, a Canaan...

BioCentury | Sep 18, 2020

Emerging Company Profile

Synthekine launches with $82M to create new cytokine signals

...in nature.  The company, which launched Thursday with an $82 million series A round co-led by Canaan...
...by K. Christopher GarciaUniversity collaborators:  Stanford UniversityCorporate partners: NoneNumber of employees: About 30Funds raised: $82 millionInvestors: Canaan...

BioCentury | Jul 21, 2020

Deals

With deal for Tizona, Gilead places latest bet on cancer immunosuppression

...Other series A investors included Amgen Ventures, Astellas Venture Management and InterWest Partners. Abingworth and Canaan...

BioCentury | May 22, 2020

Emerging Company Profile

With $60M, Canaan-incubated Day One seizes on under-appreciated advances in pediatric cancers

...trial infrastructure to make the former a driving force instead of an afterthought. Incubated by Canaan...
...has approved only 10 new drugs for pediatric cancers in the past 30 years, said Canaan...
...Pharmaceutical Co. Ltd., Sunesis Pharmaceuticals Inc. Number of employees: 22 Funds raised: $62 million Investors: Canaan...

BioCentury | May 20, 2020

Finance

$145M raise positions Rallybio to bring first rare disease program into clinic

...Global Investment Inc. also participated in the untranched round, as did existing investors 5AM Ventures, Canaan...

BioCentury | Mar 18, 2020

Politics, Policy & Law

Bay Area labs pare down to essentials following shelter-in-place directives

...receiving patient samples, running mouse studies to completion and monitoring the health of animal colonies. Canaan...
...countermeasures, is free to all who visit the site. Karen Tkach Tuzman, Associate Editor Stanford University Genentech Inc. twoXAR Inc. Biocom Canaan COVID19 COVID-19 shelter-in-place...

BioCentury | Mar 10, 2020

Politics, Policy & Law

We’ve moved on from nude women parties. The progress is much bigger than that.

...Pfizer Ventures, or the Women Who Venture dinner led by Nina Kjellson, general partner at Canaan...
...by a trio of female Chinese biopharma veterans: Samantha Du, Marietta Wu and Stella Xu. Canaan...
...general partner last year -- women now make up five of the seven members of Canaan’s...

BioCentury | Feb 06, 2020

Finance

Feb. 5 Financial Quick Takes: Aimmune gets $200M Nestlé investment; plus Vineti, MaaT, Kezar, Ziopharm, Ikarovec

...the Kite Pharma Inc. unit of Gilead Sciences Inc. (NASDAQ:GILD), as well as existing investors Canaan...

BioCentury | Jan 14, 2020

Finance

Tyra raises $50M series A for cancer drug resistance

...clinic for drug-resistant cancer. Alta Partners, RA Capital Management, Boxer Capital of Tavistock Group and Canaan...
...the company cites resistance to tyrosine kinase inhibitors as a major limitation to targeted therapy. Canaan’s...

BioCentury | Jan 11, 2020

Financial News

Pact’s $75M series C gives Vida’s Kite alumni long-sought stab at personalized cell therapy

...Pact investors. Pact’s A and B rounds were led by GV; its other investors are Canaan...

BioCentury | Dec 20, 2019

Financial News

Pathios founder attracts investors to $8.8M series A

...signaling. Canaan and Australia’s Medical Research Commercialisation Fund, managed by Brandon Capital, co-led the round. Canaan’s...
...first received funding from Brandon in a 2008 series B round and by Brandon and Canaan...
...Grey Wolf Therapeutics, for which Canaan co-led a series A round in February (see “Andera, Canaan...

BioCentury | Dec 14, 2019

Company News

Management Tracks: Alector hires new president, COO and appoints R&D committee co-chairs; plus Pyxis, Translate Bio, Canaan, PMV, Janpix, Kiadis and more

...the additional role of COO. Heartlein will become EVP and founder, a newly created position. Canaan...
...was CSO and medical director at Exagen Inc. (NASDAQ:XGN). BioCentury Staff Alector Inc. Janpix Inc. PMV Pharmaceuticals Inc. Pyxis Oncology Inc. Canaan Kiadis...

BioCentury | Dec 11, 2019

Clinical News

Iterum antibiotic fails in Phase III for intra-abdominal infections, further driving down shares

...value. According to an April proxy statement, VCs still holding stakes larger than 5% include Canaan...

BioCentury | Oct 22, 2019

Emerging Company Profile

Intrepida: Tackling the innate immune system to treat cancer

...the target will be a differentiator in the already crowded immuno-oncology space. Sofinnova Investments and Canaan...
...Therapy ”). Intrepida’s board includes Indaco’s Elizabeth Robinson, Biouniversa CEO Giovanni Rizzo, Sofinnova’s David Kabakoff, Canaan’s...
...N/A Corporate partners: N/A Number of employees: 2 Funds raised: $9.5 million Investors: Sofinnova Investments, Canaan...

BioCentury | Oct 11, 2019

Product Development

What’s next for neoantigens

...series A funds in 2016. Both rounds were led by GV, and had participation from Canaan...

BioCentury | Jun 19, 2019

Financial News

Coenzyme A company Comet debuts with $28.5M series A

...take advantage of Cambridge’s “unparalleled talent pool,” Chairman Peter Van Vlasselaer told BioCentury. New investor Canaan...
...and allow the company to expand its team and establish a pipeline. Sofinnova's Henrijette Richter, Canaan's...
...Roel Bulthuis, BioInnovation's Anthony Walsh, de Graaf and Van Vlasselaer joined Comet's board. Mary Romeo, Staff Writer Canaan Comet...

BioCentury | Jun 13, 2019

Finance

Sitting it out: Why some investors are staying out of mega-series A rounds

...inflection point? That will point you to the best fund and the best fit,” said Canaan...
...deal,” said Grant. According to BCIQ, only one of the 14 biotech series A rounds Canaan...
...platform for identifying new targets on immune-suppressive macrophages. The average size of the A rounds Canaan...

BioCentury | Jun 13, 2019

Financial News

June 13 Financial Quick Takes: Hansoh prices $1B HKEX IPO; plus Provention, Genome Medical, InGeneron and more

...Capital, Perceptive Advisors, Manatt Venture Fund and Dreamers Fund also participated, as did existing investors Canaan...

BioCentury | May 20, 2019

Product Development

Making Orphan drug prices work for society

...“Today’s predominance of Orphan medicines was not the anticipated outcome of the act.” Tim Shannon, Canaan...
...it was trying to overcome. “Rare disease medicines are increasingly the new blockbusters.” Tim Shannon, Canaan...
...expectations in return for market access. “Fundamental change will need to come externally.” Tim Shannon, Canaan...

BioCentury | May 03, 2019

Emerging Company Profile

Vineti: Keeping cell therapies on track

...Therapeutics Pte. Ltd. Vineti raised a $33.5 million series B a year ago led by Canaan...
...Corporate partners: GE Ventures, Mayo Clinic Number of employees: 85 Funds raised: $47.3 million Investors: Canaan...

BioCentury | May 01, 2019

Company News

Management tracks: Gilead, bluebird, Apollomics

...May 6. He will also join the company's board. Singhal was executive in residence at Canaan...

BioCentury | Apr 26, 2019

Financial News

Schizophrenia therapy developer Karuna among four biotechs to file for IPOs

...see "Following its Blueprint" ). Institutional investors with more than a 5% stake are 5AM, Canaan...

BioCentury | Apr 19, 2019

Company News

Emerging company roundup: Kintai, Nocion, Arrakis and more

...Mass.) also officially launched this week, raising a $27 million series A round co-led by Canaan...

BioCentury | Apr 18, 2019

Finance

Arranging Arrakis' syndicate

...Celgene Corp. (NASDAQ:CELG), the latter of which is being acquired by Bristol-Myers Squibb Co. (NYSE:BMY). Canaan...
...RNA" ). Although there was "no shortage of strategic interest in this space," according to Canaan's...

BioCentury | Apr 18, 2019

Financial News

RNA-targeting small molecule company Arrakis raises $75M series B

...WuXi AppTec Co. Ltd. (Shanghai:603259; HKSE:2359) and Alexandria Venture Investments, as well as returning investors Canaan...

BioCentury | Apr 17, 2019

Financial News

Canaan, F-Prime back pain play Nocion with $27M round

...indication, cough (see "Targeting Pain Neurons and Nothing Else" ). The round was co-led by Canaan...

BioCentury | Apr 17, 2019

Emerging Company Profile

Nocion: Targeting pain neurons and nothing else

...With a $27 million series A co-led by Canaan and F-Prime Capital announced Wednesday, Nocion thinks...
...the chemistry of the molecule so that it only gets into channels that are open.” Canaan’s...
...University collaborators: None Corporate partners: None Number of employees: 5 Funds raised: $27 million Investors: Canaan...

BioCentury | Mar 01, 2019

Product R&D

Mapping microbiome manufacturing

...move when they start to say, ‘there’s a real base of business there’.” Wende Hutton, Canaan...
...are coming into the space now, and I expect that trend to continue,” said Smith. Canaan...
...China Karen Tkach Tuzman, Associate Editor Culture Biosciences Inc. Microbiotica Ltd. PureTech Health plc Rebiotix Inc. Seres Therapeutics Inc. Synlogic Inc. Vedanta Biosciences Inc. Canaan Finch...

BioCentury | Feb 16, 2019

Finance

Andera looks early for cancer immunotherapy

...investment in preclinical company Grey Wolf Therapeutics to diversify its cancer immunotherapy portfolio. Along with Canaan...
...A round, Wisniewski, Hercend, and Canaan’s Brent Ahrens joined Grey Wolf’s board. The investment is Canaan’s...

BioCentury | Feb 16, 2019

Company News

Emerging company roundup: Passage, IFM, Grey Wolf, Culture

...therapies to increase tumor visibility. The round was led by new investors Andera Partners and Canaan...

BioCentury | Feb 15, 2019

Financial News

Andera, Canaan lead Grey Wolf £10M A round

...therapies to increase tumor visibility. The round was led by new investors Andera Partners and Canaan...
...cell death 1 Grey Wolf Therapeutics, Oxford, U.K. Business: Cancer Mark Zipkin Andera Partners Grey Wolf Therapeutics Sygnature Discovery Ltd. Canaan Endoplasmic...

BioCentury | Feb 11, 2019

Financial News

Andera, Canaan lead Grey Wolf £10M A round

...therapies to increase tumor visibility. The round was led by new investors Andera Partners and Canaan...
...Endoplasmic reticulum aminopeptidase 2; PD-1 (PDCD1; CD279) - Programmed cell death 1 Mark Zipkin Andera Partners Sygnature Discovery Ltd. Canaan Endoplasmic...

BioCentury | Nov 16, 2018

Financial News

Hillhouse, Quan lead $93M series B for immuno-oncology play NextCure

...and NS Investment also participated in the series B round, as well as existing investors Canaan...

BioCentury | Nov 13, 2018

Financial News

Hillhouse, Quan lead $93M series B for immuno-oncology play NextCure

...and NS Investment also participated in the series B round, as well as existing investors Canaan...

BioCentury | Sep 14, 2018

Financial News

OncoResponse to move into clinic with $40M series B

...Group participated, as did existing investors Alexandria Venture Investments, Arch Venture Partners, HT Family Office, Canaan...

BioCentury | Sep 11, 2018

Financial News

OncoResponse to move into clinic with $40M series B

...Group participated, as did existing investors Alexandria Venture Investments, Arch Venture Partners, HT Family Office, Canaan...

BioCentury | Aug 31, 2018

Financial News

Arvinas looking to raise $100M in IPO

...rounds (see "Arvinas Raises $55M Series C" ). Shareholders with stakes greater than 5% include Canaan...

BioCentury | Aug 30, 2018

Financial News

Arvinas looking to raise $100M in IPO

...rounds (see "Arvinas Raises $55M Series C" ). Shareholders with stakes greater than 5% include Canaan...

BioCentury | Aug 10, 2018

Finance

Super-sized ambitions

...commercialize. Those business models take hundreds of millions of dollars," said Canaan Partners' Nina Kjellson. Canaan...

BioCentury | Jul 27, 2018

Financial News

Liquidia prices $50M IPO

...a powder formulation of treprostinil delivered via dry powder inhaler. Shareholders include New Enterprise Associates, Canaan...

BioCentury | May 28, 2021

Deals

May 27 Quick Takes: EMDAC votes narrowly in favor of Provention’s teplizumab; plus BMS, Biohaven, Day One, Frazier, miRecule, Oisin and more

...its lead program, type II RAF kinase inhibitor DAY101 for pediatric low-grade glioma. Top shareholders include Canaan...

BioCentury | Jun 29, 2018

Product R&D

Highly personal

...cell therapies. In May, Pact completed a $95.5 million series B round led by GV. Canaan...
...for gene editing, joining the $120 million series B round for Editas Medicine in 2015. Canaan...
...attitude that informatics is a critical enabling tool and not just an afterthought.” Nina Kjellson, Canaan...

BioCentury | May 25, 2018

Financial News

Anti-infectives play Iterum raises $80M in IPO

...to the penem antibiotic from Pfizer Inc. (NYSE:PFE). Prior to the IPO, Sofinnova Ventures and Canaan...

BioCentury | May 18, 2018

Finance

China comes to Europe

...Ltd. (Ireland) $65.0 Series B Domain Associates , Bay City Capital , Sofinnova Ventures , Canaan...
...diseases Iterum Therapeutics Ltd. (Ireland) $65.0 Series B Domain Associates, Bay City Capital, Sofinnova Ventures, Canaan...

BioCentury | Apr 27, 2018

Financial News

Rallybio raises $37M in series A

...raised $37 million on April 25 in a series A round led by 5AM Ventures, Canaan...

BioCentury | Apr 25, 2018

Financial News

Former Alexion team launches Rallybio with $37M series A

...play Rallybio LLC raised $37 million in a series A round led by 5AM Ventures, Canaan...

BioCentury | Apr 25, 2018

Finance

Rare disease rally

...Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) executives, closed a $37 million series A round co-led by 5AM, Canaan...

BioCentury | Apr 06, 2018

Financial News

Arvinas raises $55M series C

...Invest. New investors Deerfield Management, Hillhouse Capital and Sirona Capital also participated alongside existing investors Canaan...

BioCentury | Apr 04, 2018

Financial News

Arvinas raises $55M series C

...Invest. New investors Deerfield Management, Hillhouse Capital and Sirona Capital also participated alongside existing investors Canaan...

BioCentury | Mar 16, 2018

Finance

Following its blueprint

...Capital of the Tavistock Group, and Driehaus Capital. Also participating were existing investors 5AM Ventures, Canaan...

BioCentury | Mar 16, 2018

Financial News

Synthetic lethality company Ideaya raises $94M

...Fund, Boxer Capital of the Tavistock Group and Driehaus Capital joined existing investors 5AM Ventures, Canaan...

BioCentury | Mar 15, 2018

Financial News

Synthetic lethality company Ideaya raises $94M

...Fund, Boxer Capital of the Tavistock Group and Driehaus Capital joined existing investors 5AM Ventures, Canaan...

BioCentury | Jan 11, 2018

Emerging Company Profile

Next, after T cells

...collaborators: Yale University Corporate partners: None Number of employees: 29 Funds raised: $67 million Investors: Canaan...

BioCentury | Dec 15, 2017

Company News

Arrakis in-licenses RNA-targeted small molecule IP

...March 2 ). The company raised $38 million in a series A round led by Canaan...
...Pennsylvania, Philadelphia, Pa. Arrakis Therapeutics Inc., Waltham, Mass. Business: Drug delivery Jennie Walters Arrakis Therapeutics Inc. University of Pennsylvania Canaan...

BioCentury | Dec 13, 2017

Company News

Arrakis in-licenses RNA-targeted small molecule IP

...March 2) . The company raised $38 million in a series A round led by Canaan...

BioCentury | Nov 16, 2017

Emerging Company Profile

YAP off, YAP on

...California San Francisco Corporate partners: None Number of employees: Five Funds raised: $40 million Investors: Canaan...

BioCentury | Jul 29, 2017

Finance

Going with the flow

...As early stage VC rounds continue to grow, Canaan Partners is once again planning to bump...
...and so our average deal size has crept up a bit." Nina Kjellson, Canaan When Canaan...
...In the end, Canaan X invested 40% in healthcare generally, and 29% in biopharma. Canaan...

BioCentury | Jul 28, 2017

Financial News

Canaan raises $800M fund

...Canaan Partners (San Francisco, Calif.) said it closed its eleventh fund, Canaan XI, at $800 million...
...will invest in seed and series A rounds for early stage healthcare and technology companies. Canaan...
...with $675 million (see BioCentury, Oct. 20, 2014 ). Canaan Partners , San Francisco, Calif. Mary Romeo Canaan...

BioCentury | Jul 25, 2017

Financial News

Canaan raises $800M fund

...Canaan Partners said it closed its eleventh fund, Canaan XI, at $800 million. The firm will...
...will invest in seed and series A rounds for early stage healthcare and technology companies. Canaan...
...closed its tenth fund in 2014 with $675 million (see BioCentury, Oct. 20, 2014) . Virginia Li Canaan...

BioCentury | Jul 05, 2017

Finance

Cross-border cachet

...China and existing investors Canaan Partners, WuXi Healthcare Ventures and Mission Bay Capital also participated. Canaan...
...another U.S.-China hybrid, Lead Therapeutics Inc. “We trust the people who are leading this company,” Canaan’s...
...will definitely try and push this to a much larger value inflection point.” Tim Shannon, Canaan...

BioCentury | Jul 05, 2017

Financial News

Vivace emerges from stealth with $25M series B round

...Capital China and existing investors Canaan Partners , WuXi Healthcare Ventures and Mission Bay Capital. Canaan...

BioCentury | Jun 28, 2017

Financial News

Vivace out of stealth with $40M in two rounds

...Capital China and existing investors Canaan Partners , WuXi Healthcare Ventures and Mission Bay Capital. Canaan...

BioCentury | May 26, 2017

Finance

Europe’s bellwether challenge

...bioVenture , Advent Life Sciences, Domain Associates , Bay City Capital , Frazier Healthcare , Canaan...

BioCentury | May 23, 2017

Financial News

Arix leads Iterum's $65M series B

...Associates and Bay City Capital also participated, as did existing investors Frazier Healthcare Partners , Canaan...

BioCentury | May 19, 2017

Financial News

Arix leads Iterum's $65M series B

...Associates and Bay City Capital also participated, as did existing investors Frazier Healthcare Partners , Canaan...

BioCentury | Mar 31, 2017

Financial News

Antiva Biosciences completes venture financing

...Capital. New investors NS Investment, Osage University Partners and Alexandria Venture Investments and existing investors Canaan...

BioCentury | Mar 28, 2017

Financial News

Antiva raises $22M series C round

...were new investors NS Investment, Osage University Partners and Alexandria Venture Investments and existing investors Canaan...

BioCentury | Mar 02, 2017

Finance

Drugging RNA

...With a tranched $38 million series A round led by Canaan Partners , Arrakis Therapeutics Inc...
...enter preclinical development, and readied the company to seek an A round. The introduction to Canaan...
...than any other I’ve seen. And we’re thrilled to be working with this team,” said Canaan’s...

BioCentury | Mar 02, 2017

Product R&D

RNA, meet small molecules

...On Monday, Arrakis announced the closing of a $38 million series A round led by Canaan...

BioCentury | Mar 02, 2017

Financial News

Arrakis Therapeutics completes venture financing

...Mass.) raised an undisclosed amount in a tranched $38 million series A round led by Canaan...

BioCentury | Feb 28, 2017

Financial News

Arrakis raises $38M to pursue RNA platform

...on Monday and raised a tranched $38 million series A round led by new investor Canaan...
...Bristol-Myers Squibb Co. (NYSE:BMY) acquired last year in a deal worth up to $600 million. Canaan's...

BioCentury | Feb 25, 2017

Finance

Intranasal option

...long-acting somatostatin analogs administered through intramuscular injection every four weeks. "There's no needle-free option,” said Canaan’s...
...oral somatostatin analogs in development. "We expect to have a more standardized PK." Nina Kjellson, Canaan...
...second undisclosed program, housed in Dauntless 2, through clinical proof of concept. According to Kjellson, Canaan...

BioCentury | Feb 17, 2017

Financial News

Dauntless adds $25M to series A round

...Diego, Calif.) raised $25 million in an extension of its series A round. New investor Canaan...

BioCentury | Feb 17, 2017

Financial News

Dauntless Pharmaceuticals completes venture financing

...series A round, bringing the total raised in the round to $32 million. New investor Canaan...

BioCentury | Sep 26, 2016

Finance

A premium premium

...of the merger, Tobira investors Domain Associates, Novo Ventures, Frazier Healthcare, Montreux Equity Partners and Canaan...

BioCentury | Sep 12, 2016

Financial News

Chrono Therapeutics completes venture financing

...Cota Capital; Mission Bay Capital; 5AM Ventures; Fountain Healthcare Partners; GE Ventures; Mayo Clinic ; Canaan...

BioCentury | Sep 08, 2016

Financial News

Chrono raises $47.6M in series B

...Partners, Hikma Ventures, Cota Capital and Mission Bay Capital also participated, as did existing investors Canaan...

BioCentury | Aug 16, 2016

Company News

Sorrento planning pain spinout

...$140 million in milestones. The company's investors included Frazier Healthcare Partners , Vivo Capital and Canaan...

BioCentury | Aug 08, 2016

Emerging Company Profile

Interrogating immunity

...$12.5 million so far in a series A round led by Arch Venture Partners , Canaan...
...raised: $12.5 million Investors: Alexandria Real Estate Equities, Arch Venture Partners , Baxalta Inc. , Canaan...

BioCentury | Jul 13, 2016

Financial News

Protagonist files for IPO

...an oral peptide interleukin-23 (IL-23) receptor antagonist, to treat UC. The company's largest shareholders are Canaan...

BioCentury | May 09, 2016

Financial News

Ideaya Biosciences completes venture financing

...Calif. Business: Cancer Date completed: 2016-05-03 Type: Venture financing Raised: $46 million Investors: 5AM Ventures; Canaan...

BioCentury | May 04, 2016

Financial News

Ideaya raises $46M series A

...South San Francisco, Calif.) raised $46 million in a series A round from 5AM Ventures, Canaan...

BioCentury | Apr 04, 2016

Finance

Frazier's GAIN

...March 24, Frazier led a $40 million financing by Iterum Therapeutics Ltd. with participation by Canaan...

BioCentury | Mar 28, 2016

Financial News

Iterum completes venture financing

...Ireland Business: Infectious Date completed: 2016-03-24 Type: Venture financing Raised: $40 million Investors: Frazier Healthcare; Canaan...

BioCentury | Mar 25, 2016

Financial News

Anti-infective play Iterum debuts with $40M

...Dublin, Ireland) raised $40 million in a series A round led by Frazier Healthcare Partners. Canaan...
...in 2014. Fishman was Durata's CFO and COO, and Dunne its CMO. Frazier's Patrick Heron, Canaan's...

BioCentury | Mar 14, 2016

Finance

Abingworth's early action

...to advance antibody modulators of the tumor microenvironment into clinical testing. New investors Abingworth and Canaan...

BioCentury | Mar 14, 2016

Financial News

Tizona Therapeutics completes venture financing

...Business: Cancer, Autoimmune Date completed: 2016-03-08 Type: Venture financing Raised: $43 million Investors: Abingworth Management; Canaan...

BioCentury | Mar 09, 2016

Financial News

Immunotherapy play Tizona raises $43M

...San Francisco, Calif.) raised $43 million in a series B round co-led by Abingworth and Canaan...
...was president of the Onyx Pharmaceuticals Inc. subsidiary of Amgen Inc. (NASDAQ:AMGN). Abingworth's Shelley Chu, Canaan's...

BioCentury | Jan 25, 2016

Strategy

Preclinical hunting ground

...immunobiology, dermatology and medicine and director of cancer immunology at Yale School of Medicine . Canaan...

BioCentury | Jan 11, 2016

Financial News

NextCure completes venture financing

...New Haven, Conn. Business: Cancer Date completed: 2016-01-06 Type: Venture financing Raised: $67 million Investors: Canaan...